CTIM-05. COMBINATION OF CONTROLLED INTERLEUKIN-12 GENE THERAPY WITH IMMUNE CHECKPOINT BLOCKADE IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS OF A MULTI-INSTITUTIONAL, OPEN LABEL PHASE 1 TRIAL

A published clinical trial of veledimex (V)-regulatable interleukin-12 (IL-12) gene therapy (“Controlled IL-12”) under the control of a transcriptional switch (RheoSwitch Therapeutic System(â), RTS(â)) as monotherapy in recurrent glioblastoma (rGBM) showed sustained infiltration of activated T cells...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Antonio Chiocca, E, Lukas, Rimas, Chen, Clark, Rao, Ganesh, Amidei, Christina, Buck, Jill, Hadar, Nira, Demars, Nathan, Miao, John, Estupinan, Taylor, Loewy, John, Wang, Yunxia, Gelb, Arnold, Cooper, Laurence
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650880/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.139
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars